All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Lilly, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.

2018-06-12T11:02:54.000Z

ASCO 2018 | Acalabrutinib monotherapy demonstrated good efficacy in WM

Jun 12, 2018
Share:

Bookmark this article

On Sunday 3rd June an oral abstract session took place at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting. Abstract 7501 was presented by Roger Owen, St James’s University Hospital, Leeds, on acalabrutinib use in patients with Waldenström macroglobulinemia (WM).

The phase II study was a multi-center, international and open-label trial testing the use of acalabrutinib in patients with WM. Patients were either treatment-naïve (TN), n = 14, or relapsed/refractory (R/R), n = 92. Treatment with acalabrutinib was either 100mg twice daily or 200mg every day in 28-day cycles until disease progression or unacceptable toxicity. The co-primary endpoints were investigator-assessed overall response rate (ORR) based on either the 6th IWWM criteria or the modified 3rd IWWM criteria.

Key Findings

  • ORR based on 6th IWWM criteria and modified 3rd IWWM criteria was 93% for both TN and R/R patients
  • The 24-month duration of response rate for TN vs R/R
    • 90% (95% CI, 47.3%, 98.5%) vs 82% (95% CI, 71.9%, 88.7%)
  • 24-month progression-free survival for TN vs R/R
    • 90% vs 81.9%
  • 24-month overall survival rate for TN vs R/R
    • 91.7% vs 88.9%
  • Most common Grade ≥3 adverse events (AEs) of all patients were neutropenia (16%), lower respiratory tract infection (5%) and pneumonia (7%)

Dr Owens concluded that acalabrutinib monotherapy showed high efficacy in WM in both TN and R/R patients. He noted that the “safety profile is very good, and most AEs were of low grade and very limited number of dropouts on account of AEs.”

  1. Owen R., et al. Acalabrutinib in patients (pts) with Waldenström macroglobulinemia (WM). Abstract 7501. 2018 ASCO Annual Meeting, Chicago, Illinois

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Your opinion matters

HCPs, what is your preferred format for educational content on the Lymphoma Hub?
42 votes - 79 days left ...

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox